Mostrando 2 resultados de: 2
Filtros aplicados
Subtipo de publicación
Article(2)
Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab
ArticleAbstract: Background: Apolipoprotein B (apoB) provides an integrated measure of atherogenic risk. Whether apoBPalabras claves:acute coronary syndrome, apolipoproteins B, cholesterol, LDL, Heart Disease Risk Factors, PCSK9 inhibitorsAutores:Aylward P.E., Bhatt D.L., Bittner V.A., Danchin N., Diaz R., Dilic M., Drexel H., Edelberg J.M., Goodman S.G., Gotcheva N.N., Hagström E., Hanotin C., Harrington R.A., Jukema J.W., Lecorps G., Liberopoulos E., Lopes R.D., Mahaffey K.W., Manvelian G., Marx N., McGinniss J., Moryusef A., Ostadal P., PATRICIO LOPEZ -JARAMILLO, Pecin I., Pordy R., Poulsen S.H., Prieto J.C., Reiner Z., Roe M.T., Sasiela W.J., Scemama M., Schwartz G.G., Sinnaeve P.R., Steg P.G., Szarek M., Tamby J.F., Tricoci P., Viigimaa M., White H.D., Yong H., Zeiher A.M.Fuentes:scopusRisk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes
ArticleAbstract: Background: The 2018 US cholesterol management guidelines recommend additional lipid-lowering therapPalabras claves:acute coronary syndrome, alirocumab, dyslipidemias, GUIDELINEAutores:Baccara-Dinet M.T., Bhatt D.L., Bittner V.A., DIaz R., Goodman S.G., Harrington R.A., Jukema J.W., Li Q.H., Lopes R.D., Louie M.J., Moriarty P.M., PATRICIO LOPEZ -JARAMILLO, Roe M.T., Schwartz G.G., Steg P.G., Szarek M., Vogel R., White H.D., Zeiher A.M.Fuentes:googlescopus